Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma - Execution framework for share buy-back program
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a…
Zealand Pharma Announces Financial Results for the First Three Months of 2026
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and survodutide, and strong…
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026 Financial strength to be further enhanced by…
Americans want big pharma reform. Candidates should deliver
Having spent 12 years on Capitol Hill, I know just how rare it is to find an issue with real bipartisan consensus. That's why when a new national survey shows 94% of voters blame pharmaceutical companies for the high cost of healthcare, it demands…
Royalty Pharma: Q1 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported first-quarter profit of $295 million. On a per-share basis, the New York-based company said it had profit of 53 cents. Earnings, adjusted for non-recurring…
Indian industry led by pharma to invest $20.5 billion in the US
Indian industry, led by pharmaceutical companies, shared plans of investing $20.5 billion in the US at the 2026 SelectUSA Investment Summit, reinforcing the growing role of Indian companies as investors and partners in the US economy, per a…
Innocan Pharma LPT-CBD is featured in Pain Medicine News
The article highlights expert discussion presented at PAINWeek 2025 regarding Innocan's LPT-CBD. LPT-CBD is designed to enable prolonged CBD release into the bloodstream, enhance bioavailability, and support once-monthly subcutaneous…
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript
Wednesday, May 6, 2026 at 8:00 a.m. ET Chief Executive Officer and Chairman of the Board — Pablo Legorreta Chairman, Partnering and Investments — Christopher Hite EVP, Head of Research and Investments — Marshall Urist EVP…
Indian companies pledge to invest record $20.5 billion in US; pharma in focus
Indian companies have pledged to invest a record $20.5 billion in the United States, which includes $19.1 billion in pharmaceuticals, the US embassy said on Wednesday. The commitments were made during an investment summit in Maryland, US. According…
Health deserts, hospital windfalls, and a phalanx of pharma lobbyists: Inside the most controversial healthcare program you never heard of
Keith Harvey is CEO of Cook Area Health Services, better known as Scenic Rivers Health, a group of nonprofit medical and dental clinics in the northeast Minnesota hinterlands. Scenic Rivers Health struggles to make the most of a mysterious federal…
That alone should win us the midterms': Trump wants voters to ignore higher costs, giant pharma profits and focus on drug prices
White House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The…
Idaho to receive over $24M in opioid settlement with Purdue Pharma
Local News The Office of Idaho Attorney General Raúl Labrador said the settlement follows a nearly decade-long investigation into the company. BOISE, Idaho — The state of Idaho is set to receive nearly $24.5 million, part of a…
Urogen Pharma Q1 Earnings Call Highlights
3 Bullish Biotech Stocks With Explosive Growth Trends Urogen Pharma NASDAQ: URGN reported first-quarter 2026 results that management said showed accelerating early momentum from the commercial launch of ZUSDURI, driven in part by the implementation…
Royalty Pharma Q1 Earnings Call Highlights
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX reported what executives described as a “strong start” to 2026, driven by double-digit growth in cash receipts, active capital deployment and a…
Athira Pharma (NASDAQ:LONA) Trading Down 2.2% - Should You Sell?
Athira Pharma, Inc. (NASDAQ:LONA - Get Free Report) fell 2.2% during trading on Wednesday. The company traded as low as $9.32 and last traded at $9.42. 19,694 shares traded hands during trading, a decline of 48% from the average session volume of…
Receive a Daily briefing on Pharma Industry News
Get Started